SINGAPORE, 14 APRIL 2022: Us2.ai, the Singapore-based medtech developers of FDA- cleared AI software that, for the first time ever, fully automates a complete echocardiography (heart ultrasound) report, today announced...
BrainCells, Taisho Pharmaceutical, sign licensing agreement for novel CNS program
News | 09. 27. 2007
BrainCells
BrainCells Inc. (BCI) and Taisho Pharmaceutical Co., Ltd. (Taisho) today announced that BCI has in-licensed a novel development program from Taisho that BCI will develop for central nervous system (CNS) indications, including mood disorders. Taisho retains rights to the program in Japan and China, while BCI will have rights for the remainder of the world. Financial terms were not disclosed.
